Bolt Biotherapeutics (NASDAQ:BOLT) Earns “Neutral” Rating from HC Wainwright

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports.

Bolt Biotherapeutics Stock Performance

NASDAQ:BOLT opened at $0.62 on Wednesday. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $23.82 million, a PE ratio of -0.36 and a beta of 0.92. Bolt Biotherapeutics has a twelve month low of $0.55 and a twelve month high of $1.56. The stock’s 50-day simple moving average is $0.64 and its 200 day simple moving average is $0.74.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative return on equity of 64.49% and a negative net margin of 665.56%. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.02 million. On average, analysts anticipate that Bolt Biotherapeutics will post -1.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. bought a new stake in shares of Bolt Biotherapeutics in the second quarter valued at $26,000. FMR LLC raised its holdings in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares in the last quarter. Finally, Acuitas Investments LLC boosted its position in shares of Bolt Biotherapeutics by 21.7% during the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after acquiring an additional 112,555 shares during the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.